PRAX - Why Praxis Precision Medicines Stock Is Trading Higher Tuesday | Benzinga
Praxis Precision Medicines Inc (NASDAQ:PRAX) provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with photo paroxysmal response (PPR), also known as photosensitivity.
PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
“The strength and consistency of response across both study arms, combined with a continued positive tolerability and safety profile, build on our earlier conviction that PRAX-628 has the potential to be the first precision ...